597 related articles for article (PubMed ID: 27449630)
1. Tacrolimus-loaded nanostructured lipid carriers for oral delivery - Optimization of production and characterization.
Khan S; Shaharyar M; Fazil M; Baboota S; Ali J
Eur J Pharm Biopharm; 2016 Nov; 108():277-288. PubMed ID: 27449630
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus-loaded nanostructured lipid carriers for oral delivery-in vivo bioavailability enhancement.
Khan S; Shaharyar M; Fazil M; Hassan MQ; Baboota S; Ali J
Eur J Pharm Biopharm; 2016 Dec; 109():149-157. PubMed ID: 27793753
[TBL] [Abstract][Full Text] [Related]
3. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
Khan S; Baboota S; Ali J; Narang RS; Narang JK
Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
[TBL] [Abstract][Full Text] [Related]
4. Long chain lipid based tamoxifen NLC. Part I: preformulation studies, formulation development and physicochemical characterization.
Shete H; Patravale V
Int J Pharm; 2013 Sep; 454(1):573-83. PubMed ID: 23535345
[TBL] [Abstract][Full Text] [Related]
5. Design, characterization, and in vitro cellular inhibition and uptake of optimized genistein-loaded NLC for the prevention of posterior capsular opacification using response surface methodology.
Zhang W; Li X; Ye T; Chen F; Sun X; Kong J; Yang X; Pan W; Li S
Int J Pharm; 2013 Sep; 454(1):354-66. PubMed ID: 23876384
[TBL] [Abstract][Full Text] [Related]
6. Comparative assessment of efficacy and safety potential of multifarious lipid based Tacrolimus loaded nanoformulations.
Jain S; Addan R; Kushwah V; Harde H; Mahajan RR
Int J Pharm; 2019 May; 562():96-104. PubMed ID: 30902706
[TBL] [Abstract][Full Text] [Related]
7. Formulation development of lipid nanoparticles: Improved lipid screening and development of tacrolimus loaded nanostructured lipid carriers (NLC).
Kovačević AB; Müller RH; Keck CM
Int J Pharm; 2020 Feb; 576():118918. PubMed ID: 31870954
[TBL] [Abstract][Full Text] [Related]
8. Construction and in vitro/in vivo evaluation of 17-allylamino-17-demethoxygeldanamycin (17AAG)-loaded PEGylated nanostructured lipid carriers.
Wang Z; Wang J; Yang S; Hou S
Drug Dev Ind Pharm; 2016 Jan; 42(1):91-98. PubMed ID: 25853294
[TBL] [Abstract][Full Text] [Related]
9. Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying.
Zhang X; Pan W; Gan L; Zhu C; Gan Y; Nie S
Chem Pharm Bull (Tokyo); 2008 Dec; 56(12):1645-50. PubMed ID: 19043233
[TBL] [Abstract][Full Text] [Related]
10. Design, characterization and in vivo evaluation of nanostructured lipid carriers (NLC) as a new drug delivery system for hydrochlorothiazide oral administration in pediatric therapy.
Cirri M; Maestrini L; Maestrelli F; Mennini N; Mura P; Ghelardini C; Di Cesare Mannelli L
Drug Deliv; 2018 Nov; 25(1):1910-1921. PubMed ID: 30451015
[TBL] [Abstract][Full Text] [Related]
11. Lipid based nanocarrier system for the potential oral delivery of decitabine: formulation design, characterization, ex vivo, and in vivo assessment.
Neupane YR; Srivastava M; Ahmad N; Kumar N; Bhatnagar A; Kohli K
Int J Pharm; 2014 Dec; 477(1-2):601-12. PubMed ID: 25445972
[TBL] [Abstract][Full Text] [Related]
12. Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement.
Mandpe L; Pokharkar V
Pharm Dev Technol; 2015 May; 20(3):320-9. PubMed ID: 24328553
[TBL] [Abstract][Full Text] [Related]
13. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the Quality by Design method.
Kovács A; Berkó S; Csányi E; Csóka I
Eur J Pharm Sci; 2017 Mar; 99():246-257. PubMed ID: 28012940
[TBL] [Abstract][Full Text] [Related]
14. Preparation and characteristics of nanostructured lipid carriers for control-releasing progesterone by melt-emulsification.
Yuan H; Wang LL; Du YZ; You J; Hu FQ; Zeng S
Colloids Surf B Biointerfaces; 2007 Nov; 60(2):174-9. PubMed ID: 17656075
[TBL] [Abstract][Full Text] [Related]
15. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers.
Rizwanullah M; Amin S; Ahmad J
J Drug Target; 2017 Jan; 25(1):58-74. PubMed ID: 27186665
[TBL] [Abstract][Full Text] [Related]
16. Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats.
Zhang S; Wang J; Pan J
Drug Deliv; 2016 Nov; 23(9):3696-3703. PubMed ID: 27749105
[TBL] [Abstract][Full Text] [Related]
17. A novel oral delivery system consisting in "drug-in cyclodextrin-in nanostructured lipid carriers" for poorly water-soluble drug: vinpocetine.
Lin C; Chen F; Ye T; Zhang L; Zhang W; Liu D; Xiong W; Yang X; Pan W
Int J Pharm; 2014 Apr; 465(1-2):90-6. PubMed ID: 24530388
[TBL] [Abstract][Full Text] [Related]
18. Optimization, stabilization, and characterization of amphotericin B loaded nanostructured lipid carriers for ocular drug delivery.
Lakhani P; Patil A; Wu KW; Sweeney C; Tripathi S; Avula B; Taskar P; Khan S; Majumdar S
Int J Pharm; 2019 Dec; 572():118771. PubMed ID: 31669555
[TBL] [Abstract][Full Text] [Related]
19. Nanostructured Etodolac Carriers in Transdermal Gel: Optimization and Characterization.
Patil P; Shirkhedkar A
Pharm Nanotechnol; 2023 Jun; 11(3):276-293. PubMed ID: 36635925
[TBL] [Abstract][Full Text] [Related]
20. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability.
Zhuang CY; Li N; Wang M; Zhang XN; Pan WS; Peng JJ; Pan YS; Tang X
Int J Pharm; 2010 Jul; 394(1-2):179-85. PubMed ID: 20471464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
